Sequential homoharringtonine (HHT) and interferon (IFN-A) produce high hematologic and cytogenetic response rates in Philadelphia chromosome positive (Ph) chronic myelogenous leukemia (CML).

被引：0
|
作者：
O'Brien, S
Kantarjian, H
Koller, C
Andreeff, M
Feldman, E
Keating, M
Beran, M
Freireich, E
Rios, MB
Talpaz, M
机构：
来源：
BLOOD | 1998年 / 92卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2707
引用
收藏
页码：656A / 656A
页数：1
相关论文
共 50 条
  • [1] Simultaneous homoharringtonine (HHT) and interferon alpha (IFN-α) therapy is an effective regimen in Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML).
    O'Brien, S
    Kantarjian, H
    Cortes, J
    Giles, FJ
    Beran, M
    Rios, MB
    Mallard, S
    Cheson, B
    Murgo, A
    Talpaz, M
    BLOOD, 1998, 92 (10) : 251A - 251A
  • [2] Simultaneous interferon alpha (IFN- α) and homoharringtonine (HHT) is an effective regimen in philadelphia chromosome (Ph)-positive chronic myelogenous leukemia.
    O'Brien, S
    Talpaz, M
    Giles, FJ
    Cortes, J
    Koller, C
    Beran, M
    Thomas, D
    Kantarjian, HM
    BLOOD, 1999, 94 (10) : 278B - 278B
  • [3] Suppression of clonal evolution in patients with Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML) on interferon alfa therapy (IFN-A) therapy.
    Cortes, J
    Kantarjian, H
    OBrien, S
    Beran, M
    Estey, E
    Koller, C
    Andreeff, M
    Kornblau, S
    Keating, M
    Freireich, EJ
    Talpaz, M
    BLOOD, 1996, 88 (10) : 918 - 918
  • [4] Interferon alpha (IFN-A) and low-dose cytosine arabinoside (ARA-C) therapy in Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML).
    Kantarjian, H
    OBrien, S
    Beran, M
    Koller, C
    Andreeff, M
    Rios, MB
    Keating, M
    Freireich, E
    Talpaz, M
    BLOOD, 1995, 86 (10) : 2105 - 2105
  • [5] Triple combination therapy with interferon-alpha (IFN-α),low-dose cytarabine (LDara-c) and homoharringtonine (HHT) in philadelphia chromosome (PH)-positive chronic myelogenous leukemia (CML) ln early chronic phase.
    Kantarjian, HM
    Talpaz, M
    Cortes, J
    Rios, MB
    Giles, FJ
    Thomas, D
    Andreeff, M
    Mallard, S
    Lim, J
    Murgo, A
    Cheson, B
    Keating, M
    O'Brien, S
    BLOOD, 1999, 94 (10) : 275B - 275B
  • [6] Treatment of Philadelphia chromosome (Ph)-positive early chronic phase (CP) chronic myelogenous leukemia (CML) with daily doses of interferon alpha (IFN-A) and low dose cytosine arabinoside (ara-C).
    Kantarjian, HM
    O'Brien, S
    Rios, MB
    Cortes, J
    Giles, FJ
    Andreeff, M
    Keating, MJ
    Talpaz, M
    BLOOD, 1998, 92 (10) : 246B - 246B
  • [7] Late cytogenetic and molecular response to interferon-α (IFN-α) in chronic myelogenous leukemia (CML).
    Nosari, A
    Perego, R
    Pungolino, E
    Cornacchini, G
    Gargantini, L
    Morra, E
    BLOOD, 1998, 92 (10) : 627A - 627A
  • [8] Transcription factor JunB is not methylated in Philadelphia (Ph) chromosome positive chronic myelogenous leukemia (CML).
    Hoshino, K
    Yang, H
    Canalli, AA
    Sanchez-Gonzalez, B
    Donato, N
    Kantarjian, H
    Issa, JP
    Garcia-Manero, G
    BLOOD, 2003, 102 (11) : 656A - 656A
  • [9] Thiotepa for treatment of thrombocytosis in patients with Philadelphia chromosome (Ph) - Positive chronic myelogenous leukemia (CML).
    RodriguezMonge, E
    Cortes, J
    OBrien, S
    Talpaz, M
    Kantarjian, H
    BLOOD, 1996, 88 (10) : 3530 - 3530
  • [10] WHAT IS THE SIGNIFICANCE OF CYTOGENETIC CLONAL EVOLUTION (CE) IN PATIENTS (PTS) WITH PHILADELPHIA-CHROMOSOME (PH)-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA (CML)
    MAJLIS, A
    KANTARJIAN, H
    SMITH, T
    TALPAZ, M
    OBRIEN, S
    KEATING, M
    FREIREICH, E
    BLOOD, 1994, 84 (10) : A150 - A150
12345